Complete Response Letter NDA 505b1 217294 (Jan 12, 2024)

Summary

This FDA letter, identified as NDA 217294, outlines requirements for a safety update and procedures for resubmission following deficiencies. It mandates specific data presentation for safety information, including adverse events, discontinuations, and worldwide experience, and sets a one-year deadline for resubmission or other actions under 21 CFR 314.110.

Key points

• Include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b) when responding to deficiencies.
• Describe in detail any significant changes or findings in the safety profile.
• Incorporate new safety data when assembling sections describing discontinuations due to adverse events, serious adverse events, and common adverse events.
• Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
• Present tabulations of the new safety data combined with the original application data.
• Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies.
• For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
• Present a retabulation of the reasons for premature trial discontinuation by incorporating drop-outs from newly completed trials.

Cited reasons

• Comprehensive Safety Update Required
• Detailed Description of Safety Profile Changes
• Inadequate Presentation of New and Combined Safety Data
• Retabulation of Premature Trial Discontinuations
• Missing Case Report Forms and Narrative Summaries for Safety Events
• Analysis of Changes in Incidence of Common Adverse Events
• Missing Updated Clinical Exposure Information
• Incomplete Worldwide Safety Experience Summary

Recommended actions

• Include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b) when responding to deficiencies.
• Describe in detail any significant changes or findings in the safety profile.
• Incorporate new safety data when assembling sections describing discontinuations due to adverse events, serious adverse events, and common adverse events.
• Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
• Present tabulations of the new safety data combined with the original application data.
• Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies.
• For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
• Present a retabulation of the reasons for premature trial discontinuation by incorporating drop-outs from newly completed trials.

Deficiency summary

The FDA issued a Complete Response Letter primarily due to significant deficiencies in the safety data presentation and analysis. The agency requires a comprehensive safety update, detailed descriptions of safety profile changes, proper incorporation and comparison of new safety data, retabulation of trial discontinuations, submission of case report forms and narrative summaries for critical safety events, analysis of common adverse event incidence changes, updated clinical exposure information, a summary of worldwide safety experience, and English translations of foreign labeling. Additionally, the sponsor is advised to consider human factors implications if product revisions impact the user interface, though this is not an approvability issue.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

NDA

Impact

Impact score

0.95

Estimated delay

545 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary theme of the Complete Response Letter is the inadequacy and incompleteness of the safety data package, requiring extensive updates, detailed analyses, and proper presentation of clinical trial adverse events, discontinuations, worldwide experience, and foreign labeling to ensure a comprehensive understanding of the product's safety profile.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 5%